BILL ANDERSON was named CEO of Genentech, which is a member of the Roche Group, effective Jan. 1, 2017. He takes over from Ian T. Clark who retires at the end of 2016 after 14 years of service. Anderson, who is also the head of North American commercial operations, has served in a number of...
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
